Therapeutic methods using vadadustat

Abstract

This invention provides methods for the treatment of anemia in patients with chronic kidney disease (CKD) using vadadustat (Compound 1), including methods suitable for conversion, correction, and maintenance therapy for patients. For example, methods described herein are durable, with efficacy observed for 24-52 weeks. Methods described herein can be particularly beneficial for patients converting from a previous anemia treatment comprising administration of an erythropoietin stimulating agent (ESA) such as darbepoetin alfa (DA), CKD patients on dialysis (e.g., peritoneal dialysis or hemodialysis), or CKD patients having certain hemoglobin (Hb) levels. 20 26 21 39 96 05 A ug 2 02 6 A B S T R A C T 2 0 2 6 2 1 3 9 9 6 0 5 A u g 2 0 2 6

Images